Inactive Instrument

Highlights Tyme Technologies, Inc.

Equities

TYME

US90238J1034

Highlights

Unlock all the news: Be the first to know and act before the market!

Syros Pharmaceuticals Closes Tyme Technologies Merger, Private Placement	17/22/17	MT
Tyme Technologies, Inc. Announces Board Changes	17/22/17	CI
Syros Pharmaceuticals, Inc. completed the acquisition of Tyme Technologies, Inc. from a group of shareholders.	16/22/16	CI
Syros Pharmaceuticals, Tyme Technologies Shares Surging in Late Trade After Shareholder Merger Nod	16/22/16	MT
Tyme Technologies, Inc. Reports Earnings Results for the First Quarter Ended June 30, 2022	09/22/09	CI
Syros Pharmaceuticals to Acquire Tyme Technologies in All-Stock Deal	05/22/05	MT
Earnings Flash (TYME) TYME TECHNOLOGIES Posts 2022 Loss of $-0.14	25/22/25	MT
Tyme Technologies, Inc. Reports Earnings Results for the Full Year Ended March 31, 2022	25/22/25	CI
Tyme Technologies to Explore Strategic Options; Shares Rise Pre-Bell	29/22/29	MT
TYME Technologies, Inc. Announces SM-88 Poster at the American Association for Cancer Research Annual Meeting 2022	09/22/09	CI
Tyme Technologies Narrows Fiscal Q3 Loss	11/22/11	MT
Tyme Technologies, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021	11/22/11	CI
Tyme Technologies, Inc. Provides Update on Precision Promise Trial in Metastatic Pancreatic Cancer	26/22/26	CI
Tyme Technologies Hit With Potential Delisting Notice After Stock Price Drops Under $1 Per Share	30/21/30	MT
Tyme Technologies, Inc. Announces Additional Encouraging Preclinical Data on the Effect of TYME-19 in SARS CoV-2 Infections	14/21/14	CI
Earnings Flash (TYME) TYME TECHNOLOGIES Reports Q2 Loss $-0.03	08/21/08	MT
Tyme Technologies, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2021	08/21/08	CI
TYME Technologies, Inc. Announces First Patient Dosed in Phase II OASIS Trial Evaluating the Potential Benefits of Oral SM-88 for Patients with Metastatic HR+/HER2- Breast Cancer After Treatment with a CDK4/6 Inhibitor	27/21/27	CI
Tyme Technologies to Seek Acquisitions	10/21/10	CI
Tyme Technologies : Earnings Flash (TYME) TYME TECHNOLOGIES Reports Q1 Loss $-0.03	10/21/10	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Tyme Technologies, Inc.

Equities

TYME

US90238J1034

Highlights

Filters